BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the safety and efficacy of BGB324 given together with
standard treatment, pembrolizumab or dabrafenib and trametinib, compared to standard
treatment alone,